Tacrolimus and pimecrolimus for atopic eczema - guidance (TA82)

National Institute for Health and Care Excellence - NICE
Publication date:
25 August 2004


Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

Since the guidance on topical pimecrolimus and tacrolimus was issued, a safety review by the European Medicines Agency has recommended greater caution in the way these medicines are used to reduce potential risks of skin cancer and lymphoma.

People who are using tacrolimus and pimecrolimus should not stop or modify their treatment without consulting their prescribing healthcare professional.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in July 2015. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.